MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | MicrobiomeTrials← Back to trialsNCT06712875
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-04-01Est. Completion: 2028-12
Enrollment target: 27 participants Locations- Children's National Hospital, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Other microbiome trials you might be interested in
Cancer Harboring BRAF AlterationsHGGLGGSolid Tumors
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF a…
Beverly Hills, United StatesEst. completion Dec 31, 2027
Low Grade AstrocytomaLow Grade GliomaMetastatic Low Grade AstrocytomaMetastatic Low Grade GliomaWHO Grade 1 Glioma
WHO Grade 2 Glioma
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincr…
Birmingham, United StatesEst. completion Dec 31, 2030
Neurological Cancer
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive n…
Boston, United StatesEst. completion Jan 1, 2027